Indazole compounds and pharmaceutical compositions for...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S338000, C514S406000, C546S256000, C546S275700, C548S362500

Reexamination Certificate

active

07053107

ABSTRACT:
Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

REFERENCES:
patent: 5476511 (1995-12-01), Gwon et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5773019 (1998-06-01), Ashton et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5824072 (1998-10-01), Wong
patent: 5834504 (1998-11-01), Tang et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6071935 (2000-06-01), Lyssikatos
patent: 6080769 (2000-06-01), Lyssikatos et al.
patent: 6150377 (2000-11-01), Lyssikatos et al.
patent: 6194438 (2001-02-01), Yang et al.
patent: 6258824 (2001-07-01), Yang
patent: 6284764 (2001-09-01), Kath et al.
patent: 6465449 (2002-10-01), Kath et al.
patent: 6479513 (2002-11-01), Yang
patent: 6495564 (2002-12-01), Lyssikatos et al.
patent: 6511993 (2003-01-01), Dack et al.
patent: 6531491 (2003-03-01), Kania et al.
patent: 6534524 (2003-03-01), Kania et al.
patent: 6586447 (2003-07-01), Lyssikatos et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6884890 (2005-04-01), Kania et al.
patent: 6891044 (2005-05-01), Kania et al.
patent: 2003/0166675 (2003-09-01), Yang
patent: 606046 (1994-07-01), None
patent: 780386 (1997-06-01), None
patent: 0818442 (1998-01-01), None
patent: 0931788 (1999-07-01), None
patent: 1004578 (2000-05-01), None
patent: 1081137 (2001-03-01), None
patent: 1106612 (2001-06-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/27583 (1996-03-01), None
patent: WO 96/14843 (1996-05-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 99/07675 (1999-02-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/62890 (1999-12-01), None
patent: WO 00/37107 (2000-06-01), None
patent: WO 00/38665 (2000-07-01), None
patent: WO 00/38715 (2000-07-01), None
patent: WO 00/38716 (2000-07-01), None
patent: WO 00/38717 (2000-07-01), None
patent: WO 00/38718 (2000-07-01), None
patent: WO 00/38719 (2000-07-01), None
patent: WO 00/38730 (2000-07-01), None
patent: WO 00/38786 (2000-07-01), None
patent: WO 01 002369 (2001-01-01), None
patent: WO 01/40217 (2001-06-01), None
patent: WO 01 53268 (2001-07-01), None
patent: WO 03/015608 (2003-02-01), None
Alon, et al., “Vascular Endothelial Growth Factor Acts as a Survival Factor For Newly Formed Retinal Vessels and Had Implications for Retinopathy of Prematurity,”Nature Medicine, 1995, 1024-1028, vol. 1, No. 10.
Folkman, et al., “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease,”Nature Medicine., 1995, 27-31, vol. 1, No. 1.
Jeffrey, Philip D., et al., “Mechanism of CDK Activation Revealed By the Structure of a CyclinA-CDK2 Complex,”Nature, Jul. 27, 1995, 313-320, vol. 376.
Lee, et al., “New Synthetic Cluster Ligands for Galactose/N-Acetylgalactosamine-Specific Lectin of Mammalian Liver,”Biochemistry, 1984, 4255-4261, vol. 23.
Lutty, et al., “A New Technique for Visualization of the Human Retinal Vasculature,”Arch. Ophthalmol., 1992, 267-276, vol. 110.
Merenmies, et al., “Receptor Tyrosine Kinase Signaling in Vascular Development,”Cell Growth&Differentiation, 1997, 3-10, vol. 8.
Mohammadi, et al., “Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor Receptor 1 and Elucidation of Their Importance in Receptor Activation and Signal Transduction,”Molecular and Cellular Biology, 1996, 977-989, vol. 16, No. 3.
Parsat, et al., “Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a Key Enzyme in Angiogenesis,”Biochemistry, 1998, 16788-16801, vol. 37.
Penn, John S., et al., “The Range of PaO2Variation Determines the Severity of Oxygen-Induced Retinopathy in Newborn Rats,”Investigative Opthalmology&Visual Science, 1995, 2063-2070, vol. 36, No. 10.
Still, et al., “Rapid Chormatographic Technique for Preparative Separations with Moderate Resolution,”J. Org. Chem., 1978, 2923-2925, vol. 43, No. 14.
Stone, J., et al., “Development of Retinal Vasculature is Mediated by Hypoxia-Induced Vascular Endothelial Growth Factor (VEGF) Expression by Neuroglia,”The Journal of Neuroscience, 1995, 4738-4747, vol. 15, No. 7.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Indazole compounds and pharmaceutical compositions for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indazole compounds and pharmaceutical compositions for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole compounds and pharmaceutical compositions for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3547590

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.